Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).

What symbol and exchange does Braveheart Bio shares trade?

Braveheart Bio trades on the NASDAQ stock market under the symbol BRVE.

What is Braveheart Bio stock price doing today?

As of October 27, 2026, BRVE stock price declined to $21.82 with 148,052 million shares trading.

How much is Braveheart Bio worth?

BRVE has a market cap of $1.96 billion. This is considered a Small Cap stock.

What are the top ETFs holding Braveheart Bio?

The top ETF exchange traded funds that BRVE belongs to (by Net Assets): VTI, VXF, SCHA, ONEQ, SCHB.

What are the support and resistance levels for Braveheart Bio (BRVE)?

BRVE support price is $20.70 and resistance is $23.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BRVE shares will trade within this expected range on the day.